Additional Features in the Treatment of Patients with Chronic Heart Failure. From EMPA-REG OUTCOME Study to EMPEROR-REDUCED Study. Resolution of the On-line Scientific Meeting of Moscow Experts
A. Yu. Lebedeva,
O. M. Koteshkova,
O. N. Dzhioeva,
S. R. Gilyarevsky,
T. M. Uskach,
M. S. Novikova,
Ya. A. Orlova,
V. Yu. Kalashnikov,
D. V. Privalov,
N. A. Ananicheva,
M. Yu. Gilyarov,
A. D. Erlikh https://doi.org/10.20996/1819-6446-2021-01-03
Abstract
The results of the international multicenter study EMPEROR-REDUCED were reviewed the on-line scientific meeting of Moscow experts on October 30, 2020. Some proposals and recommendations for further study of the cardiovascular and renal effects of empagliflozin and its use in clinical practice in patients with chronic heart failure with reduced ejection fraction were accepted.
About the Authors
A. Yu. LebedevaRussian Federation
Anastasia Yu. Lebedeva
eLibrary SPIN: 5700-5075
O. M. Koteshkova
Russian Federation
Olga M. Koteshkova
eLibrary SPIN: 6141-1224
O. N. Dzhioeva
Russian Federation
Olga N. Dzhioeva
eLibrary SPIN: 1803-5454
S. R. Gilyarevsky
Russian Federation
Sergey R. Gilyarevsky
eLibrary SPIN: 1683-2709
T. M. Uskach
Russian Federation
Tatiana M. Uskach
eLibrary SPIN: 8752-9657
M. S. Novikova
Russian Federation
Maria S. Novikova
eLibrary SPIN: 5227-0554
Ya. A. Orlova
Russian Federation
Yana A. Orlova
eLibrary SPIN: 3153-8373
V. Yu. Kalashnikov
Russian Federation
Victor Yu. Kalashnikov
eLibrary SPIN: 5342-7253
D. V. Privalov
Russian Federation
Dmitry V. Privalov
N. A. Ananicheva
Russian Federation
Natalia A. Ananicheva
eLibrary SPIN: 2247-0561
M. Yu. Gilyarov
Russian Federation
Mikhail Yu. Gilyarov
eLibrary SPIN: 7713-6726
A. D. Erlikh
Russian Federation
Alexey D. Erlikh
eLibrary SPIN: 4697-0822
References
1. Koudstaal S., Pujades-Rodriguez M., Denaxas S., et al. Prognostic burden of heart failure recorded in primary care, acute hospital admissions, or both: a population-based linked electronic health record cohort study in 2.1 million people. Eur J Heart Fail. 2017;19(9):1119-27. DOI:10.1002/ejhf.709.
2. Jones N.R., Roalfe A.K., Adoki I., et al. Survival of patients with chronic heart failure in the community: a systematic review and meta-analysis. Eur J Heart Fail. 2019;21(11):1306-25. DOI:10.1002/ejhf.1594.
3. Zinman B., Wanner C., Lachin J.M., et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015;373(22):2117-28. DOI:10.1056/NEJMoa1504720.
4. Wanner C., Inzucchi S.E., Lachin J.M., et al. Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. N Engl J Med. 2016;375(4):323-34. DOI:10.1056/NEJMoa1515920.
5. Packer M. SGLT2 inhibitors produce cardiorenal benefits by promoting adaptive cellular reprogramming to induce a state of fasting mimicry: a paradigm shift in understanding their mechanism of action. Diabetes Care 2020;43:508-11. DOI:10.2337/dci19-0074.
6. Packer M., Anker S.D., Butler J., et al. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. N Engl J Med. 2020;383(15):1413-24. DOI:10.1056/NEJMoa2022190.
7. Packer M., Anker S.D., Butler J., et al. Effect of Empagliflozin on the Clinical Stability of Patients with Heart Failure and a Reduced Ejection Fraction: The EMPEROR-Reduced Trial. Circulation. 2020 Oct 21. DOI:10.1161/CIRCULATIONAHA.120.051783.
8. Instructions for the medical use of Jardins® LP-002735 [cited 10/01/2020]. Available at: http://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=74ca831d-640f-4bcf-ae60-b17253a6d72d&t= (In Russ.)
Review
For citations:
Lebedeva A.Yu., Koteshkova O.M., Dzhioeva O.N., Gilyarevsky S.R., Uskach T.M., Novikova M.S., Orlova Ya.A., Kalashnikov V.Yu., Privalov D.V., Ananicheva N.A., Gilyarov M.Yu., Erlikh A.D. Additional Features in the Treatment of Patients with Chronic Heart Failure. From EMPA-REG OUTCOME Study to EMPEROR-REDUCED Study. Resolution of the On-line Scientific Meeting of Moscow Experts. Rational Pharmacotherapy in Cardiology. 2021;17(1):165-168. (In Russ.) https://doi.org/10.20996/1819-6446-2021-01-03
Views:
558
Email this article 